The present study addressed the evaluation of the recently synthesized THRβ agonist TG68 on hepatic fat accumulation and liver injury in mice fed HFD, a model closely recapitulating the complex pathological events associated with NAFLD in humans. This evidence concerns the gene THRB and metabolic dysfunction-associated steatotic liver disease.